Enterprise Value
568.1M
Cash
319.4M
Avg Qtr Burn
-5.097M
Short % of Float
6.84%
Insider Ownership
7.07%
Institutional Own.
40.25%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lupkynis (Voclosporin) Details Lupus nephritis | Approved Quarterly sales | |
Voclosporin Ophthalmic Solution Details Dry eye syndrome | Failed Discontinued | |
Voclosporin Details Focal segmental glomerulosclerosis | Failed Discontinued |